Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: T1DM - Type 1 Diabetes Mellitus Clear all
Completed Not applicable Interventional Results available

Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System

NCT01390259
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Open-Loop, Closed-Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 6, 2026, 1:00 PM EDT
Terminated No phase listed Observational

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

NCT01767831
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iBOLUSED
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 6, 2026, 1:00 PM EDT
Recruiting Not applicable Interventional

Very Low Carbohydrate Diets and Glucagon Response in T1DM

NCT04200391
View directory record Official record
Conditions
Type1diabetes
Interventions
Very low carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Feasibility and Efficacy of Delivering Blood Glucose Awareness Training Over the Internet

NCT00327210
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood Glucose Awareness Training
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM

NCT00760526
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Continuous glucose monitor, Home blood glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 9 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional

iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes

NCT02980627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Eating Disorders
Interventions
Therapy with Mobile App Enhancement
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Concord, California • Encino, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 6, 2026, 1:00 PM EDT
Completed No phase listed Observational

Vascular Inflammation in Adolescents With Type 1 Diabetes

NCT00933101
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 6, 2026, 1:00 PM EDT
Terminated Phase 2 Interventional Results available

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 6, 2026, 1:00 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Triple Therapy in T1DM

NCT03899402
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus

NCT01418703
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed Loop Control (CLC), Open Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

NCT02656069
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

NCT03216226
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
dasiglucagon, GlucaGen
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth

NCT05168657
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1, Autoimmune Diabetes, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Insulin-Dependent, 1, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis-Prone, Diabetes Mellitus, Sudden-Onset, Insulin-Dependent Diabetes Mellitus 1, Juvenile-Onset Diabetes, Type 1 Diabetes Mellitus
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

NCT02673138
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
canagliflozin, basal interruption without canagliflozin
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

NCT02666430
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
39
States / cities
Fresno, California • Greenbrae, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 6, 2026, 1:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 6, 2026, 1:00 PM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 6, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

NCT00073255
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
hokt3g1 (ALA-ALA)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 6, 2026, 1:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus

NCT00001985
View directory record Official record
Conditions
Diabetes Mellitus, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 6, 2026, 1:00 PM EDT
Withdrawn Phase 2 Interventional

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Type 1
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 6, 2026, 1:00 PM EDT